Amycretin, Novo Nordisk’s dual GLP-1/amylin agonist, posted real Phase 2 weight-loss numbers in both injectable and oral form and is now advancing to Phase 3 for obesity. Here’s how it compares to retatrutide and CagriSema.
SURMOUNT-5 put tirzepatide and semaglutide in the same trial, head to head. The result: 20.2% vs 13.7% average weight loss. Here’s what that gap actually means.
The FDA expanded Rybelsus’s approval in October 2025 to include cardiovascular risk reduction for adults with type 2 diabetes, closing the gap between oral and injectable semaglutide’s proven benefits.
Novo Nordisk filed CagriSema with the FDA in December 2025, backed by REDEFINE trial data showing 22.7% average weight loss. Here’s how the semaglutide-plus-amylin combination actually works.
The FDA approved the Wegovy pill — oral semaglutide 25mg — on December 22, 2025, delivering 16.6% average weight loss in the OASIS 4 trial. Here’s how it differs from Rybelsus and Lilly’s rival Foundayo.
Research overview of GLP-1 receptor agonists: the GLP-1 mechanism, approved drugs and their clinical trial data (STEP, SELECT, SURMOUNT), and the investigational pipeline.
GLP-1 receptor agonists are being studied in female reproductive health contexts — including PCOS, ovarian function, and fertility outcomes. Here is what published research reports.
Emerging research has examined GLP-1 receptor expression in reproductive tissue. This covers what published studies report about GLP-1 signaling and male reproductive biology.
Understanding the tolerability profiles reported in research studies is important context for evaluating peptide research. This overview covers what animal and early human studies have reported.
Growth hormone secretagogues and anabolic peptides are among the most-studied compounds in the performance research space. Here is what the published evidence actually shows.
